Bristol-Myers Squibb Co
BRM
Company Profile
Business description
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Bristol derives close to 70% of total sales from the US, showing a higher dependence on the US market than most of its peer group.
Contact
Route 206 and Province Line Road
Princeton
New JerseyNJ08543
USAT: +1 609 252-4621
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - General
Fiscal Year End
31 December 2025
Employees
34,100
Stocks News & Analysis
stocks
The best way to get rich and retire early
This goes through the different options including shares, property and business ownership and declares a winner, as well as outlining the mindset needed to earn enough to never have to work again.
stocks
Investors overly negative on cheap ASX share
We cut our fair value by 26% but the market has overreacted.
stocks
Overvalued US AI play reports earnings
Strong earnings with high projected growth but price is too rich.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,096.20 | 77.60 | 0.86% |
| CAC 40 | 8,110.22 | 10.85 | -0.13% |
| DAX 40 | 24,318.31 | 34.34 | 0.14% |
| Dow JONES (US) | 48,362.68 | 227.79 | 0.47% |
| FTSE 100 | 9,879.52 | 13.55 | 0.14% |
| HKSE | 25,774.14 | 27.63 | -0.11% |
| NASDAQ | 23,428.83 | 121.21 | 0.52% |
| Nikkei 225 | 50,412.87 | 10.48 | 0.02% |
| NZX 50 Index | 13,517.73 | 9.43 | 0.07% |
| S&P 500 | 6,878.49 | 43.99 | 0.64% |
| S&P/ASX 200 | 8,795.70 | 78.80 | 0.90% |
| SSE Composite Index | 3,919.98 | 2.61 | 0.07% |